Table 1.
Patients’ characteristics
| Summary of 71 patients | ||
|---|---|---|
| Age (mean) | 67 (range-34–94) | |
| Male/female | 29/34 | |
| Lymphocyte count at time of study (103/μl) (average) | 58 (range-6–300) | |
| Doubling time | Less then six month | 11 |
| More then six month | 24 | |
| NA* | 36 | |
| RAI stage | 0–I | 36 |
| II | 15 | |
| III | 7 | |
| IV | 13 | |
| ZAP-70 (PCR) | positive | 22 |
| negative | 22 | |
| NA | 27 | |
| Serum IgG | <700 mg/dl | 21 |
| >700 mg/dl | 25 | |
| NA | 25 | |
| Autoimmune phenomena** | 7 | |
| Previous chemotherapy | Leukeran/prednisone | 9 |
| FCR | 17 | |
| chlorambucil | 3 | |
| none | 47 |
*
Due to recurrent courses of chemotherapy.
**
Includes Coomb’s positive hemolytic anemia, Evan’s syndrome, immune thryroiditis and Sjögren’s disease.
L/P-Leukeran/Prednisone, FC/R-Fludarabine and Endoxan with or without Rituximab.